Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Investors are increasingly unsettled by a sequence of policy choices and abrupt regulatory actions in Indonesia that followed a downgrade of its sovereign outlook and criticism from an index provider. Market responses - including a weak government debt auction, a currency trading near record lows, and a lagging equity benchmark - suggest growing co…
European equity indices slipped modestly on Tuesday as markets digested the implementation of a new U.S. tariff framework and a stream of corporate results. Investors also tracked gains in oil prices ahead of another round of U.S.-Iran nuclear talks, while auto sales data and sector-specific earnings provided mixed signals for financials, healthcar…
Vodafone Group Plc has issued a notice of redemption for its 4.375% notes due in May 2028. The company will redeem the securities at a price equal to the greater of (1) 100% of principal plus accrued interest or (2) the present value of remaining scheduled payments discounted using an adjusted treasury rate plus 25 basis points; the discount uses a…
Grupo Aeroportuario del Pacífico and Grupo Aeroportuario del Centro Norte reported fourth-quarter 2025 results that showed EBITDA growth year-over-year but fell short of analyst expectations due to higher operating costs. GAPB posted MXN5.1 billion in EBITDA, up about 8% despite a 1% drop in passenger traffic, while OMAB reported MXN2.58 billion, a…
On the fourth anniversary of Russia's full-scale invasion, President Volodymyr Zelenskiy said Ukraine has defended its independence and will pursue peace without betraying the sacrifices made by its people. Dignitaries from European partners are due to attend ceremonies in Kyiv as stalled U.S.-brokered talks remain deadlocked over territory.
Over four years of conflict in Ukraine, low-cost first-person-view (FPV) drones and an expanding array of longer-range unmanned systems have transformed battlefields. Armoured manoeuvre is now constrained by near-constant aerial threat, medical evacuations are slowed, and logistics routes must be defended by mobile drone-hunting teams. The shift ha…
India's statistics office will roll out a revised national accounts series on February 27 that changes how real GDP is calculated, adopting more granular price deflation and moving toward double deflation. The overhaul expands the set of items used to deflate nominal output from about 180 to roughly 500-600 drawn from a new consumer price index and…
Shinhan Financial (SHG) is trading near $69.93 with strong technical momentum, single-digit P/E and sub-1.0 P/B. With management emphasizing shareholder returns and a clear path to lift ROE, the stock looks actionable for a medium-term swing: enter at $69.93, stop $66.00, target $77.00. Key risks include elevated short activity, near-term overbough…
OC Oerlikon reported fourth-quarter orders and sales that exceeded consensus, driven by double-digit organic order growth. The company flagged a materially higher book gain from the sale of Barmag, which supports a large special dividend and debt repayment, while full-year operational metrics largely matched or slightly beat analyst expectations de…
Solvay reported Q4 adjusted EBITDA of €169 million, modestly ahead of some analyst estimates yet slightly below consensus, while sales missed expectations. The Belgian chemicals group set fiscal 2026 targets for underlying EBITDA and free cash flow that come in below analyst and consensus forecasts and underneath the company's dividend payout targe…
dormakaba Holding AG reported first-half results that missed consensus on revenues and adjusted EBITDA, driven by weaker volumes and a significant negative foreign exchange impact. Net sales reached CHF1,363 million, with organic growth of 2.0% driven by price increases of 2.6% while volumes declined 0.6%. Group adjusted EBITDA came in at CHF212 mi…
Japan's equity market closed higher on Tuesday, with the Nikkei 225 rising 0.83% as gains in the Real Estate, Banking and Textile sectors supported broader advances. Several individual stocks recorded large percentage moves, with Furukawa Electric, Murata Manufacturing and Fujikura among the top gainers, while Trend Micro, Sumitomo Dainippon Pharma…
Tesla's new-car registrations in the European Union dropped 17% year-on-year in January to 8,075 vehicles, pushing the company's market share down to 0.8% from 1.0%. The decline comes amid a modest overall fall in EU car registrations and a rising share for battery-electric vehicles, according to industry data.
Amazon's recent pullback prices in a higher capex run that will depress free cash flow near term. But with AWS profitability, healthy ROE, a reasonable P/S multiple and technical oversold conditions, a long trade at current levels offers asymmetric upside. This idea lays out an entry, stop and target for a 180-trading-day trade and a clear checklis…
<p>Bitcoin extended a recent slide on Tuesday, falling nearly 4% to around $63,131 and wiping out roughly 50% of the gains from its early-October record high. Traders pointed to uncertainty over U.S. tariff policy, heavy selling by both institutional and retail participants, and on-chain flows from large holders as the main drivers of the rout. Mos…
RBC Capital initiated coverage of Eagle Materials Inc. with a Sector Perform rating and a $208 price target, noting the shares currently trade above that level. The firm argues that splitting the company's lightside and heavyside operations could unlock substantial shareholder value, while recent quarterly results and a downgrade from JPMorgan comp…
UBS downgraded Enhabit Home Health & Hospice (NYSE: EHAB) from Buy to Neutral while increasing its price target to $13.80 following the company’s agreement to be acquired by Kinderhook Industries for $13.80 per share in cash. The transaction, which places Enhabit’s total enterprise value near $1.1 billion, has led multiple research firms to revise …
Canaccord Genuity has initiated coverage of Americas Gold and Silver Corporation (NYSE: USAS) with a Buy rating and a C$17.00 price target, a level that reflects a 1.0x fully risked net asset value measured to January 1, 2027. The firm notes a 57% implied return to its target from the current share price, while recent company results show a Q3 2025…
UBS cut its rating on Arcellx Inc. to Neutral from Buy while lifting the price target to $115 per share after Gilead Sciences announced a definitive agreement to acquire Arcellx for $115 per share in cash plus a $5 contingent value right. The transaction values Arcellx at a total equity value of $7.8 billion and has triggered a sharp share rally an…
Leerink Partners downgraded Gossamer Bio to Market Perform from Outperform and cut its price target to $1.00 from $6.00 after topline results from the Phase 3 PROSERA study missed statistical significance on the primary Six-Minute Walk Distance endpoint. The shares plunged roughly 80% over the prior week to $0.42, valuing the company at about $98 m…
Stifel cut its rating on DT Midstream to Hold from Buy while raising the price target to $137. The firm praised the company’s backlog and utility growth exposure, but said the stock’s valuation - trading above 14 times 2027 EBITDA and near a 52-week high - prompted the downgrade. DT Midstream reported mixed fourth-quarter 2025 results with an EPS m…
Jefferies upgraded Ashmore Group from Hold to Buy and raised its price target to GBP2.85 from GBP1.70, citing a turning point in the emerging market cycle in Q4 2025 that generated $2.6 billion of net new money. The broker points to sizable institutional reallocation into emerging markets, strong recent share-price gains, attractive valuation metri…
Pliant Therapeutics is a highly discounted clinical-stage biotech trading at roughly $76M market cap. The stock has been depressed by a paused BEACON-IPF trial and investor litigation, but an upcoming or recent lapse of a shareholder rights plan (poison pill) could allow strategic buyers to accumulate and force a revaluation. This trade idea buys t…
JPMorgan downgraded Novo Nordisk to Neutral from Overweight and cut its price target to DKK250 from DKK350 after clinical trial results for the company’s experimental obesity drug, CagriSema, fell short of expectations versus a competing therapy. The bank substantially reduced sales and earnings forecasts for CagriSema and trimmed broader group rev…
Oppenheimer maintained an Outperform rating and a $15.00 price target on ORIC Pharmaceuticals after the company released fourth-quarter and full-year 2025 results. Analysts highlighted encouraging clinical signals for multiple candidates and noted the company’s strong liquidity position, while market watchers flag valuation and upcoming class-level…
